SCYNEXIS ^{Priced, Nasdaq: SCYX}

Biotech developing treatments for life-threatening fungal infections.

Industry: Health Care

First Day Return: -10.0%

SCYX

Biotech developing treatments for life-threatening fungal infections.

IPO News for SCYNEXIS

Fungus fighter Cidara Therapeutics sets terms for $60 million IPO 04/06/15
Fungus beware: Cidara Therapeutics files for a $69 million IPO 03/13/15
SCYNEXIS prices IPO at $10, as expected 05/02/14

IPO Data
IPO Date	05/01/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$62
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Durham, NC, United States
Founded	1999
Employees at IPO	90
Website www.scynexis.com

IPO News for SCYNEXIS

Fungus fighter Cidara Therapeutics sets terms for $60 million IPO 04/06/15
Fungus beware: Cidara Therapeutics files for a $69 million IPO 03/13/15
SCYNEXIS prices IPO at $10, as expected 05/02/14

SCYNEXIS (SCYX) Performance